Molecular Mass: 380.275 g/mol
Molecular Formula: C18H22BrNO3
25B-NBOMe which also goes by the name 2C-B-NBOMe is a structural derivative of the popular psychedelic substituted phenethylamine 2-CB.
Other common names include Cimbi-36, Nova, New Nexus and BOM 2-CB.
This chemical goes by the systematic and formal IUPAC name 2- (4-bromo-2,5-dimethoxyphenyl) -N- [(2-methoxyphenyl) methyl]ethanamine, has an empirical chemical formula of C18H22BrNO3 and molar mass of 380.275 grams.
This fine chemical is a recent psychoactive compound which was first synthesised in 2004 by the chemist Ralf Heim whilst undertaking research at the Free University of Berlin.
25B-NBOMe diverges structurally from 2-CB by substitution of the primary amine in 2-CB with a 2-methoxybenzely moiety (BOMe). The 2-methoxybenzyl substitution at the amine is a defining feature of the NBOMe series. In the particular instance of 25B-NBOMe a methoxy ether is bound at ring R2 at position 2.
Pharmacologically 25B-NBOMe is a potent partial agonist at the serotenergic 5HT2A receptor. This is a common feature of seretonergic psychadelics. Other psychedelic chemicals with this interaction include LSD, psilocybin (the primary psychoactive agent in magic mushrooms), DMT, Mescaline (the primary psychoactive alkaloid in peyote cactus), chemicals from the 2C series such as 2CE and 2CB and the other members of the NBOMe family of chemicals. These can be collectively labelled as the serotonergic psychedelics. Exactly how the psychedelic experiences may arise from this interaction at the 5HT2a receptor is unknown.
25B-NBOMe is a highly novel chemical entity that has no history of recorded human consumption prior to 2010. It has not been analysed scientifically for its toxicological or physiological effects in humans.
25B-NBOMe is therefore not for consumption in animals and humans. Any reports of usage are unverified and information pertaining to effects should be taken as such.
It is reported online that 25B-NBOMe has a long duration of action with effects lasting from between 12-16 hours after administration. The chemical is reported to be inactive when taken orally and instead users will choose a sublingual method of administration where the substance is placed and maintained within the mouth for sufficient time to allow absorption at the buccal cavity.
25-NBOMe has very high potency. Users report threshold effects with as little as 50 µg. Common doses are reported in the range of 300-500 µg . As with all highly novel compounds it is advised to begin with lower doses due to unpredictable effects owing to differences in individual sensitivities, tolerance, metabolism and body mass.
Unlike some psychedelics such as LSD , 25-NBOMe can be fatal in cases of overdose. Caution is therefore advised with respect to dosage.
Effects commonly reported online include stimulation, feelings of weightlessness, tactile body sensations, numbing of the mouth and unpleasant taste, nausea and vomiting, feelings of empathy and love towards others, rapid thoughts, distortion of perception of time, feelings of wakefulness, increased appreciation of music, heightened emotions, memory suppression, increased libido, colour enhancement, increased visual acuity, tracers, after images and visuals similar to LSD.
25B-NBOMe is not reported as being a habit forming substance and should have low addiction potential.
There is however potential for harm in dosage. Users should never insufflate this compound as this is potentially lethal.Harm reduction methods should be practiced.